Open AccessEffect of Transdermal Teriparatide Administration on Bone Mineral Density in Postmenopausal Women
Author(s) -
Felicia Cosman,
Nancy E. Lane,
Michael A. Bolognese,
José Zanchetta,
Pedro Alberto García-Hernández,
Karen H. Sees,
James A. Matriano,
Kim Gaumer,
Peter E. Daddona
Publication year - 2009
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2009-0358
Subject(s) - medicine , transdermal , placebo , teriparatide , bone mineral , osteoporosis , n terminal telopeptide , transdermal patch , context (archaeology) , bone remodeling , urology , bone density , pharmacology , chemistry , paleontology , biochemistry , alkaline phosphatase , alternative medicine , pathology , osteocalcin , biology , enzyme
Treatment of osteoporosis with an anabolic agent, teriparatide [human PTH 1-34 (TPTD)], is effective in reducing incident fractures, but patient resistance to daily sc injections has limited its use. A novel transdermal patch, providing a rapid, pulse delivery of TPTD, may provide a desirable alternative.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom